Supernus rises after FDA approves its drug-device combination for Parkinson's disease

Supernus Pharmaceuticals

04/02/2025 16:08

** Shares of Supernus Pharmaceuticals  SUPN.O  rise 6.2% to
$39.67
    ** SUPN says U.S. FDA has approved its drug-device
combination, Onapgo, to treat movement-related symptoms of
Parkinson's disease
    ** Approval comes after previous declines in 2022 and 2024
due to quality and device concerns
    ** SUPN says Onapgo will be available in United States in Q2
and is expected to generate $200 mln to 300 mln in peak sales
    ** SUPN gained 30.4% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))